Showing 1441-1450 of 2656 results for "".
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Ideaya Biosciences and Boston Children’s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndromehttps://modernod.com/news/ideaya-biosciences-and-boston-childrens-hospital-collaborate-on-preclinical-evaluation-of-ide196-for-sturge-weber-syndrome/2477220/Ideaya Biosciences announced that the company has entered into a Sponsored Research Agreement with Boston Children’s Hospital for preclinical evaluation of the role of protein kinase C (PKC) in Sturge Weber syndrome (SWS), a rare neurocutaneous disorder characterized by capillary malformati
- Johnson & Johnson Vision’s Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Resultshttps://modernod.com/news/johnson-johnson-visions-investigational-antihistamine-releasing-contact-lens-demonstrates-positive-phase-3-results/2476418/Johnson & Johnson Vision announced that results from two phase 3 clinical studies evaluating the company’s investigational antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen) were published in the journal Cornea. The results demonstrated that patients weari
- Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with J&J’s Janssenhttps://modernod.com/news/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-jjs-janssen/2476272/Morphic Therapeutic announced that it has entered into a research and development collaboration with Johnson & Johnson’s subsidiary Janssen Biotech, to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson &a
- Johnson & Johnson Vision Launches the UK’s First Free Nationwide Recycling Program for all Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-launches-the-uks-first-free-nationwide-recycling-program-for-all-contact-lenses/2476189/Johnson & Johnson Vision has launched the Acuvue Contact Lens Recycle Program, the UK’s first free nationwide program that enables consumers to easily recycle their contact lenses and the blister and foil packaging after use. The program is available to all soft contact lens wearers reg
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 17th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education and patient care, Basco
- Rayner’s New UK-Based Manufacturing Facility Receives FDA Approvalhttps://modernod.com/news/rayners-new-uk-based-manufacturing-facility-receives-fda-approval/2479988/The FDA has approved Rayner’s Ridley Innovation Centre, a $40 million purpose-built R&D, training and production facility in Worthing, UK, according to a company news release. This state-of-the-art, dedicated IOL production center has the capability of manufacturing 3 million IOLs each
- Former P&G And Cincinnati Children’s Executive Katherine Overbey Joins OneSight As President And Executive Directorhttps://modernod.com/news/former-pg-and-cincinnati-childrens-executive-katherine-overbey-joins-onesight-as-president-and-executive-director/2480057/Global vision care nonprofit OneSight announced that Katherine “K-T” Overbey will be joining the organization as President and Executive Director. Ms. Overbey brings a distinct blend of blue-chip corporate and nonprofit experience in both developed and emerging markets, as well as a s
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <
- Japan’s Health Ministry Approves World’s First Trials for Using iPS Cells to Treat Corneal Diseasehttps://modernod.com/news/japans-health-ministry-approves-worlds-first-trials-for-using-ips-cells-to-treat-corneal-disease/2476363/The health ministry conditionally approved the world’s first clinical study to treat patients with corneal disease by using induced pluripotent stem (iPS) cells, according to a